Takeda Pharmaceutical (TAK) Financials

$14.17 +0.45 (+3.28%)

Closing price 08/1/2025 03:59 PM Eastern

Extended Trading

$14.13 -0.04 (-0.28%)

As of 08/1/2025 07:56 PM Eastern

Annual Income Statements for Takeda Pharmaceutical

This table shows Takeda Pharmaceutical's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	3/31/2017	3/31/2018	3/31/2019	3/31/2020	3/31/2021	3/31/2022	3/31/2023	3/31/2024
Net Income / (Loss) Attributable to Common Shareholders	1,032	1,758	1,214	413	3,399	1,894	2,388	953
Consolidated Net Income / (Loss)	1,037	1,757	1,213	413	3,401	1,895	2,388	954
Net Income / (Loss) Continuing Operations	1,037	1,757	1,213	413	3,401	1,895	2,388	954
Total Pre-Tax Income	1,287	2,044	1,146	-567	3,311	2,492	2,826	349
Total Operating Income	1,399	2,275	2,135	937	4,604	3,795	3,695	1,416
Total Gross Profit	10,534	11,992	12,982	20,543	19,919	20,275	20,967	18,761
Total Revenue	15,550	16,658	18,835	30,712	28,908	29,389	30,339	28,196
Operating Revenue	15,550	16,658	18,835	30,712	28,908	29,389	30,339	28,196
Total Cost of Revenue	5,016	4,666	5,853	10,169	8,988	9,114	9,372	9,434
Operating Cost of Revenue	5,016	4,666	5,853	10,169	8,988	9,114	9,372	9,434
Total Operating Expenses	9,134	9,717	10,847	19,606	15,316	16,480	17,272	17,346
Selling, General & Admin Expense	5,558	5,910	6,445	9,002	7,916	7,299	7,513	6,969
Marketing Expense	1,407	1,149	1,604	4,250	3,814	3,894	4,086	4,312
Research & Development Expense	2,804	3,062	3,308	4,595	4,121	4,332	4,771	4,827
Other Operating Expenses / (Income)	-1,289	-1,594	-1,436	-562	-2,875	-355	-192	-128
Impairment Charge	654	1,191	926	2,321	2,340	1,310	1,094	1,366
Total Other Income / (Expense), net	-112	-231	-989	-1,504	-1,293	-1,303	-869	-1,067
Interest Expense	209	300	748	1,540	2,248	1,372	1,278	1,454
Interest & Investment Income	110	372	151	260	954	195	474	344
Other Income / (Expense), net	-14	-303	-392	-224	0.69	-127	-65	43
Income Tax Expense	250	287	-67	-980	-90	596	437	-604
Net Income / (Loss) Attributable to Noncontrolling Interest	-5.14	1.67	1.01	-0.46	-1.50	-0.88	-0.16	-0.86
Basic Earnings per Share	$147.15	$239.35	$140.61	$28.41	$240.72	$1.21	$1.54	$0.61
Weighted Average Basic Shares Outstanding	-	-	1.57B	1.56B	1.72B	1.67B	1.69B	1.69B
Diluted Earnings per Share	$146.26	$237.56	$139.82	$28.25	$238.96	$1.20	$1.52	$0.60
Weighted Average Diluted Shares Outstanding	-	-	1.57B	1.56B	1.72B	1.67B	1.69B	1.69B
Weighted Average Basic & Diluted Shares Outstanding	-	-	1.57B	1.56B	1.72B	1.67B	1.69B	1.69B

No quarterly income statements for Takeda Pharmaceutical are available.

This table details how cash moves in and out of Takeda Pharmaceutical's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	3/31/2017	3/31/2018	3/31/2019	3/31/2020	3/31/2021	3/31/2022	3/31/2023	3/31/2024
Net Change in Cash & Equivalents	-938	-392	3,943	-404	2,858	-1,196	-2,554	-674
Net Cash From Operating Activities	2,346	3,555	-2,950	6,250	9,139	9,248	7,361	4,737
Net Cash From Continuing Operating Activities	2,346	3,555	2,950	6,182	11,218	9,313	7,412	4,832
Net Income / (Loss) Continuing Operations	1,037	1,757	1,213	413	3,401	1,895	2,388	954
Consolidated Net Income / (Loss)	1,037	1,757	1,213	413	3,401	1,895	2,388	954
Depreciation Expense	1,539	1,714	2,225	5,446	5,059	4,802	5,005	4,814
Non-Cash Adjustments To Reconcile Net Income	-241	44	-36	2,325	1,837	2,023	1,842	2,143
Changes in Operating Assets and Liabilities, net	11	41	-451	-2,003	922	593	-1,823	-3,079
Net Cash From Investing Activities	-5,887	-878	-25,467	2,726	3,557	-1,631	-4,573	-3,067
Net Cash From Continuing Investing Activities	-5,887	-878	-25,465	2,726	3,557	-1,631	-4,573	-2,847
Purchase of Property, Plant & Equipment	-1,006	-1,207	-1,204	-2,032	-2,138	-1,532	-4,774	-3,179
Acquisitions	-5,289	-267	-26,572	-46	0.00	-409	0.00	0.00
Purchase of Investments	-109	-834	-154	-70	-114	-69	-76	-45
Sale of Property, Plant & Equipment	24	28	455	117	420	15	7.25	57
Divestitures	578	800	765	4,307	4,795	232	60	132
Sale and/or Maturity of Investments	98	478	665	581	688	191	233	214
Other Investing Activities, net	-183	122	577	-132	-93	-60	-23	-26
Net Cash From Financing Activities	2,603	-3,069	26,460	-9,380	-9,839	-8,813	-5,342	-2,344
Net Cash From Continuing Financing Activities	2,603	-3,069	26,460	-9,380	-9,839	-8,813	-5,342	-2,741
Repayment of Debt	-1,820	-5,221	2,794	-11,286	-17,604	-7,889	-3,530	-3,147
Repurchase of Common Equity	-208	-176	0.00	-35	-334	-638	-203	-15
Payment of Dividends	-1,272	-1,335	-1,284	-2,637	-2,562	-2,336	-2,105	-1,899
Issuance of Debt	5,990	3,702	25,110	4,630	10,663	2,053	565	2,493
Other Financing Activities, net	-88	-38	-150	-52	-1.55	-3.17	-69	-173

No quarterly cash flow statements for Takeda Pharmaceutical are available.

This table presents Takeda Pharmaceutical's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2018	2019	2020	2021	2022	2023	2024
Period end date	3/31/2018	3/31/2019	3/31/2020	3/31/2021	3/31/2022	3/31/2023	3/31/2024
Total Assets	38,636	123,873	119,640	116,726	108,515	105,143	99,913
Total Current Assets	10,150	26,880	23,044	24,524	21,357	18,064	16,920
Cash & Equivalents	2,771	6,305	5,950	8,735	6,997	4,019	3,027
Accounts Receivable	3,954	6,663	7,064	7,079	5,737	4,892	4,420
Inventories, net	2,041	12,653	8,556	7,002	7,025	7,546	8,062
Current Deferred & Refundable Income Taxes	80	65	260	268	228	243	193
Other Current Assets	1,304	1,194	1,213	1,441	1,370	1,364	1,217
Plant, Property, & Equipment, net	5,051	11,962	12,937	13,143	13,034	12,740	13,158
Plant, Property & Equipment, gross	5,051	11,962	12,937	13,143	13,034	12,740	13,158
Total Noncurrent Assets	23,435	85,030	83,660	79,058	74,124	74,339	69,835
Long-Term Investments	1,016	972	1,002	3,149	2,718	2,854	2,848
Goodwill	9,684	38,082	37,443	36,466	36,296	36,088	35,776
Intangible Assets	9,543	42,670	38,925	35,338	31,444	32,163	28,268
Noncurrent Deferred & Refundable Income Taxes	611	799	2,875	3,198	2,985	2,757	2,605
Other Noncurrent Operating Assets	2,582	2,508	3,415	907	680	477	339
Total Liabilities & Shareholders' Equity	38,636	123,873	119,640	116,726	108,515	105,143	99,913
Total Liabilities	19,655	77,297	75,526	69,924	61,714	57,274	51,811
Total Current Liabilities	6,939	22,929	20,304	16,029	17,669	18,696	15,296
Short-Term Debt	0.17	8,846	5,476	200	1,680	2,558	2,429
Accounts Payable	2,260	2,940	2,975	3,108	4,251	4,891	3,621
Current Deferred & Payable Income Tax Liabilities	637	1,353	1,705	1,313	1,654	1,750	727
Other Current Liabilities	3,763	9,365	9,255	11,408	10,083	9,497	8,520
Total Noncurrent Liabilities	12,716	54,368	55,221	53,895	44,044	38,577	36,514
Long-Term Debt	9,274	42,803	42,052	41,703	34,103	30,454	29,603
Noncurrent Deferred & Payable Income Tax Liabilities	854	7,035	7,139	5,212	3,896	2,224	781
Noncurrent Employee Benefit Liabilities	824	1,406	1,461	1,436	1,201	961	951
Other Noncurrent Operating Liabilities	1,765	3,124	4,568	5,544	4,845	4,939	5,179
Total Equity & Noncontrolling Interests	18,981	46,575	44,115	46,801	46,801	47,869	48,102
Total Preferred & Common Equity	18,793	46,539	44,077	46,764	46,797	47,865	48,097
Preferred Stock	854	14,821	15,680	15,263	14,072	13,023	11,555
Total Common Equity	17,939	31,719	28,398	31,500	32,725	34,842	36,542
Common Stock	733	14,761	15,566	15,080	13,803	12,628	11,087
Retained Earnings	14,652	14,329	12,784	13,649	12,185	11,609	9,200
Treasury Stock	-700	-513	-816	-538	-955	-756	-339
Other Equity Adjustments	3,299	3,142	864	3,310	7,692	11,361	16,594
Noncontrolling Interest	188	36	37	37	4.15	4.14	4.90

No quarterly balance sheets for Takeda Pharmaceutical are available.

This table displays calculated financial ratios and metrics derived from Takeda Pharmaceutical's official financial filings.

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	3/31/2017	3/31/2018	3/31/2019	3/31/2020	3/31/2021	3/31/2022	3/31/2023	3/31/2024
Growth Metrics	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	7.13%	13.07%	63.06%	-5.87%	1.66%	3.23%	-7.06%
EBITDA Growth	0.00%	26.02%	7.65%	55.25%	56.89%	-12.35%	1.94%	-27.36%
EBIT Growth	0.00%	42.33%	-11.62%	-59.08%	545.67%	-20.33%	-1.05%	-59.82%
NOPAT Growth	0.00%	73.41%	15.55%	-70.97%	620.97%	-38.95%	8.19%	23.81%
Net Income Growth	0.00%	69.39%	-30.94%	-65.93%	722.79%	-44.26%	26.01%	-60.07%
EPS Growth	0.00%	62.42%	-41.14%	-79.80%	745.88%	-99.50%	26.64%	-60.37%
Operating Cash Flow Growth	0.00%	51.51%	-182.98%	311.85%	46.22%	1.20%	-20.41%	-35.64%
Free Cash Flow Firm Growth	0.00%	0.00%	-182.41%	110.01%	109.43%	-49.31%	-71.01%	82.42%
Invested Capital Growth	0.00%	0.00%	269.23%	-6.33%	-10.24%	-5.15%	1.56%	0.34%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-	-	-	-
Gross Margin	67.74%	71.99%	68.92%	66.89%	68.91%	68.99%	69.11%	66.54%
EBITDA Margin	18.81%	22.12%	21.06%	20.06%	33.43%	28.82%	28.46%	22.25%
Operating Margin	9.00%	13.66%	11.33%	3.05%	15.93%	12.91%	12.18%	5.02%
EBIT Margin	8.91%	11.84%	9.25%	2.32%	15.93%	12.48%	11.96%	5.17%
Profit (Net Income) Margin	6.67%	10.55%	6.44%	1.35%	11.76%	6.45%	7.87%	3.38%
Tax Burden Percent	80.58%	85.96%	105.85%	-72.90%	102.71%	76.07%	84.52%	273.15%
Interest Burden Percent	92.89%	103.63%	65.76%	-79.50%	71.90%	67.92%	77.84%	23.94%
Effective Tax Rate	19.42%	14.04%	-5.85%	0.00%	-2.71%	23.93%	15.48%	-173.15%
Return on Invested Capital (ROIC)	0.00%	15.80%	3.89%	0.74%	5.82%	3.86%	4.25%	5.22%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	8.91%	-0.25%	0.18%	2.11%	0.32%	1.44%	-5.93%
Return on Net Nonoperating Assets (RNNOA)	0.00%	2.71%	-0.19%	0.17%	1.66%	0.19%	0.79%	-3.23%
Return on Equity (ROE)	0.00%	18.51%	3.70%	0.91%	7.48%	4.05%	5.05%	1.99%
Cash Return on Invested Capital (CROIC)	0.00%	-184.20%	-110.86%	7.28%	16.62%	9.14%	2.70%	4.88%
Operating Return on Assets (OROA)	0.00%	5.10%	2.14%	0.59%	3.90%	3.26%	3.40%	1.42%
Return on Assets (ROA)	0.00%	4.55%	1.49%	0.34%	2.88%	1.68%	2.24%	0.93%
Return on Common Equity (ROCE)	0.00%	17.49%	2.80%	0.60%	4.93%	2.78%	3.60%	1.48%
Return on Equity Simple (ROE_SIMPLE)	0.00%	9.35%	2.61%	0.94%	7.27%	4.05%	4.99%	1.98%
Net Operating Profit after Tax (NOPAT)	1,128	1,955	2,260	656	4,729	2,887	3,123	3,867
NOPAT Margin	7.25%	11.74%	12.00%	2.14%	16.36%	9.82%	10.29%	13.71%
Net Nonoperating Expense Percent (NNEP)	0.00%	6.90%	4.14%	0.56%	3.72%	3.54%	2.82%	11.14%
Cost of Revenue to Revenue	32.26%	28.01%	31.08%	33.11%	31.09%	31.01%	30.89%	33.46%
SG&A Expenses to Revenue	35.74%	35.48%	34.22%	29.31%	27.38%	24.84%	24.76%	24.72%
R&D to Revenue	18.03%	18.38%	17.56%	14.96%	14.25%	14.74%	15.73%	17.12%
Operating Expenses to Revenue	58.74%	58.33%	57.59%	63.84%	52.98%	56.07%	56.93%	61.52%
Earnings before Interest and Taxes (EBIT)	1,385	1,972	1,743	713	4,604	3,668	3,630	1,458
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	2,925	3,685	3,967	6,159	9,664	8,470	8,635	6,273
Valuation Ratios	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	0.80	0.90	0.75	0.79	0.64
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.74	0.98	0.84	0.91	0.83
Price to Earnings (P/E)	0.00	0.00	0.00	55.02	8.37	13.01	11.50	24.70
Dividend Yield	0.00%	0.00%	2.25%	5.72%	4.58%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	1.82%	11.95%	7.69%	8.70%	4.05%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.92	0.96	0.89	0.90	0.82
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	2.57	2.55	2.20	2.20	2.17
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	12.83	7.63	7.65	7.72	9.76
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	110.79	16.02	17.66	18.35	42.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	120.46	15.60	22.44	21.33	15.84
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	12.64	8.07	7.00	9.05	12.93
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	12.26	5.47	9.47	33.60	16.93
Leverage & Solvency	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.49	1.11	1.08	0.90	0.76	0.69	0.67
Long-Term Debt to Equity	0.00	0.49	0.92	0.95	0.89	0.73	0.64	0.62
Financial Leverage	0.00	0.30	0.77	0.95	0.79	0.60	0.55	0.54
Leverage Ratio	0.00	2.04	2.48	2.69	2.60	2.41	2.26	2.14
Compound Leverage Factor	0.00	2.11	1.63	-2.13	1.87	1.63	1.76	0.51
Debt to Total Capital	0.00%	32.82%	52.58%	51.86%	47.24%	43.33%	40.82%	39.97%
Short-Term Debt to Total Capital	0.00%	0.00%	9.01%	5.98%	0.23%	2.03%	3.16%	3.03%
Long-Term Debt to Total Capital	0.00%	32.82%	43.58%	45.89%	47.01%	41.29%	37.65%	36.94%
Preferred Equity to Total Capital	0.00%	3.02%	15.09%	17.11%	17.21%	17.04%	16.10%	14.42%
Noncontrolling Interests to Total Capital	0.00%	0.67%	0.04%	0.04%	0.04%	0.01%	0.01%	0.01%
Common Equity to Total Capital	0.00%	63.49%	32.29%	30.99%	35.51%	39.63%	43.08%	45.60%
Debt to EBITDA	0.00	2.52	13.02	7.72	4.34	4.22	3.82	5.11
Net Debt to EBITDA	0.00	1.49	11.18	6.59	3.11	3.08	3.03	4.17
Long-Term Debt to EBITDA	0.00	2.52	10.79	6.83	4.32	4.03	3.53	4.72
Debt to NOPAT	0.00	4.74	22.86	72.47	8.86	12.40	10.57	8.28
Net Debt to NOPAT	0.00	2.81	19.64	61.87	6.35	9.03	8.37	6.76
Long-Term Debt to NOPAT	0.00	4.74	18.94	64.12	8.82	11.81	9.75	7.66
Altman Z-Score	0.00	0.00	0.00	0.63	0.87	0.82	0.84	0.75
Noncontrolling Interest Sharing Ratio	0.00%	5.49%	24.25%	33.71%	34.12%	31.38%	28.63%	25.62%
Liquidity Ratios	-	-	-	-	-	-	-	-
Current Ratio	0.00	1.46	1.17	1.13	1.53	1.21	0.97	1.11
Quick Ratio	0.00	0.97	0.57	0.64	0.99	0.72	0.48	0.49
Cash Flow Metrics	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-22,791	-64,365	6,442	13,493	6,839	1,983	3,617
Operating Cash Flow to CapEx	238.91%	301.57%	-393.87%	326.50%	532.03%	609.65%	154.44%	151.73%
Free Cash Flow to Firm to Interest Expense	0.00	-75.87	-86.05	4.18	6.00	4.99	1.55	2.49
Operating Cash Flow to Interest Expense	11.24	11.83	-3.94	4.06	4.07	6.74	5.76	3.26
Operating Cash Flow Less CapEx to Interest Expense	6.54	7.91	-4.95	2.82	3.30	5.64	2.03	1.11
Efficiency Ratios	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.43	0.23	0.25	0.24	0.26	0.28	0.28
Accounts Receivable Turnover	0.00	4.21	3.55	4.47	4.09	4.59	5.71	6.06
Inventory Turnover	0.00	2.29	0.80	0.96	1.16	1.30	1.29	1.21
Fixed Asset Turnover	0.00	3.30	2.21	2.47	2.22	2.25	2.35	2.18
Accounts Payable Turnover	0.00	2.06	2.25	3.44	2.96	2.48	2.05	2.22
Days Sales Outstanding (DSO)	0.00	86.64	102.87	81.57	89.29	79.58	63.94	60.27
Days Inventory Outstanding (DIO)	0.00	159.67	458.16	380.63	315.89	280.88	283.76	301.92
Days Payable Outstanding (DPO)	0.00	176.83	162.16	106.16	123.51	147.37	178.03	164.64
Cash Conversion Cycle (CCC)	0.00	69.47	398.87	356.04	281.66	213.09	169.66	197.56
Capital & Investment Metrics	-	-	-	-	-	-	-	-
Invested Capital	0.00	24,747	91,371	85,585	76,821	72,868	74,008	74,258
Invested Capital Turnover	0.00	1.35	0.32	0.35	0.36	0.39	0.41	0.38
Increase / (Decrease) in Invested Capital	0.00	24,747	66,625	-5,787	-8,764	-3,953	1,140	250
Enterprise Value (EV)	0.00	0.00	0.00	79,009	73,765	64,780	66,624	61,249
Market Capitalization	0.00	0.00	0.00	22,715	28,445	24,637	27,457	23,532
Book Value per Share	$0.00	$0.00	$20.27	$18.15	$20.22	$19.02	$20.91	$21.57
Tangible Book Value per Share	$0.00	$0.00	($31.33)	($30.65)	($25.87)	($20.35)	($20.05)	($16.23)
Total Capital	0.00	28,255	98,224	91,643	88,704	82,583	80,881	80,133
Total Debt	0.00	9,274	51,649	47,528	41,903	35,782	33,012	32,031
Total Long-Term Debt	0.00	9,274	42,803	42,052	41,703	34,103	30,454	29,603
Net Debt	0.00	5,487	44,372	40,577	30,020	26,067	26,139	26,156
Capital Expenditures (CapEx)	982	1,179	749	1,914	1,718	1,517	4,766	3,122
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	440	6,492	2,265	-39	-1,629	-2,094	1,025
Debt-free Net Working Capital (DFNWC)	0.00	3,211	12,797	8,215	8,695	5,368	1,926	4,052
Net Working Capital (NWC)	0.00	3,211	3,952	2,739	8,495	3,688	-633	1,623
Net Nonoperating Expense (NNE)	91	199	1,046	243	1,328	991	735	2,913
Net Nonoperating Obligations (NNO)	0.00	5,766	44,796	41,470	30,020	26,067	26,139	26,156
Total Depreciation and Amortization (D&A)	1,539	1,714	2,225	5,446	5,059	4,802	5,005	4,814
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	2.64%	34.47%	7.38%	-0.14%	-5.54%	-6.90%	3.63%
Debt-free Net Working Capital to Revenue	0.00%	19.28%	67.94%	26.75%	30.08%	18.27%	6.35%	14.37%
Net Working Capital to Revenue	0.00%	19.28%	20.98%	8.92%	29.39%	12.55%	-2.09%	5.76%
Earnings Adjustments	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$113.50	$28.41	$240.72	$147.14	$204.29	$0.61
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	1.57B	1.56B	1.72B	1.67B	1.69B	1.69B
Adjusted Diluted Earnings per Share	$0.00	$0.00	$112.86	$28.25	$238.96	$145.87	$201.94	$0.60
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	1.57B	1.56B	1.72B	1.67B	1.69B	1.69B
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	1.57B	1.56B	1.72B	1.67B	1.69B	1.69B
Normalized Net Operating Profit after Tax (NOPAT)	1,655	2,979	2,143	2,280	4,861	3,883	4,048	1,947
Normalized NOPAT Margin	10.64%	17.88%	11.38%	7.43%	16.82%	13.21%	13.34%	6.91%
Pre Tax Income Margin	8.28%	12.27%	6.08%	-1.85%	11.45%	8.48%	9.31%	1.24%
Debt Service Ratios	-	-	-	-	-	-	-	-
EBIT to Interest Expense	6.64	6.56	2.33	0.46	2.05	2.67	2.84	1.00
NOPAT to Interest Expense	5.40	6.51	3.02	0.43	2.10	2.10	2.44	2.66
EBIT Less CapEx to Interest Expense	1.93	2.64	1.33	-0.78	1.28	1.57	-0.89	-1.14
NOPAT Less CapEx to Interest Expense	0.70	2.59	2.02	-0.82	1.34	1.00	-1.29	0.51
Payout Ratios	-	-	-	-	-	-	-	-
Dividend Payout Ratio	122.66%	76.00%	105.83%	638.03%	75.33%	123.24%	88.13%	199.16%
Augmented Payout Ratio	142.67%	86.04%	105.83%	646.46%	85.15%	156.93%	96.63%	200.78%

No quarterly metrics and ratios for Takeda Pharmaceutical are available.

Frequently Asked Questions About Takeda Pharmaceutical's Financials

When does Takeda Pharmaceutical's fiscal year end?

According to the most recent income statement we have on file, Takeda Pharmaceutical's financial year ends in March. Their financial year 2024 ended on March 31, 2024.

How has Takeda Pharmaceutical's net income changed over the last 7 years?

Takeda Pharmaceutical's net income appears to be on an upward trend, with a most recent value of $953.56 million in 2024, falling from $1.04 billion in 2017. The previous period was $2.39 billion in 2023. See Takeda Pharmaceutical's forecast for analyst expectations on what’s next for the company.

What is Takeda Pharmaceutical's operating income?

Takeda Pharmaceutical's total operating income in 2024 was $1.42 billion, based on the following breakdown:

Total Gross Profit: $18.76 billion
Total Operating Expenses: $17.35 billion

How has Takeda Pharmaceutical's revenue changed over the last 7 years?

Over the last 7 years, Takeda Pharmaceutical's total revenue changed from $15.55 billion in 2017 to $28.20 billion in 2024, a change of 81.3%.

How much debt does Takeda Pharmaceutical have?

Takeda Pharmaceutical's total liabilities were at $51.81 billion at the end of 2024, a 9.5% decrease from 2023, and a 163.6% increase since 2018.

How much cash does Takeda Pharmaceutical have?

In the past 6 years, Takeda Pharmaceutical's cash and equivalents has ranged from $2.77 billion in 2018 to $8.73 billion in 2021, and is currently $3.03 billion as of their latest financial filing in 2024.

How has Takeda Pharmaceutical's book value per share changed over the last 7 years?

Over the last 7 years, Takeda Pharmaceutical's book value per share changed from 0.00 in 2017 to 21.57 in 2024, a change of 2,156.9%.

Related Companies

This page (NYSE:TAK) was last updated on 8/2/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Takeda Pharmaceutical (TAK) Financials

Frequently Asked Questions About Takeda Pharmaceutical's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Takeda Pharmaceutical (TAK) Financials

Annual Income Statements for Takeda Pharmaceutical

Quarterly Income Statements for Takeda Pharmaceutical

Annual Cash Flow Statements for Takeda Pharmaceutical

Quarterly Cash Flow Statements for Takeda Pharmaceutical

Annual Balance Sheets for Takeda Pharmaceutical

Quarterly Balance Sheets for Takeda Pharmaceutical

Annual Metrics And Ratios for Takeda Pharmaceutical

Quarterly Metrics And Ratios for Takeda Pharmaceutical

Frequently Asked Questions About Takeda Pharmaceutical's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools